| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2467 | h1-agonist-39 | Novel full H1 agonist |
|
| DCC2468 | H2-003 | Novel class of selective diacylglycerol acyltransferase 2 (DGAT2) inhibitor |
|
| DCC2469 | H2-005 | Novel class of selective diacylglycerol acyltransferase 2 (DGAT2) inhibitor |
|
| DCC2470 | H2a-4t | Novel water-soluble and biocompatible small-molecule near-infrared II (NIR-II) fluorescent dye |
|
| DCC2471 | h2lassbio-1064 | Inhibitor of acetic acid-induced writhing response |
|
| DCC2472 | H-4073 | Novel inhibitor of STAT3 activation, inhibiting head and neck cancer cell proliferation in a dose dependent manner |
|
| DCC2473 | H77-77 | Inhibitor of monoamine oxidase (MAO) |
|
| DCC2474 | Ha Protein Inhibitor 1 | Novel hemagglutinin (HA) protein inhibitor, inhibiting entry and replication of diverse influenza viruses via the HA protein, showing potent antiviral activity against diverse H1N1, H5N1, and H3N2 influenza viruses encoding HA proteins from both groups 1 |
|
| DCC2475 | Halauxifen | Herbicide, being used for the control of broad-leaved weeds in cereals and oilseed rape |
|
| DCC2476 | Halobetasol | Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictor activities, inducing phospholipase A2 inhibitory proteins, activating gene expression of anti-inflammatory proteins mediated via the corticosteroid receptor response element |
|
| DCC2477 | Halofantrine Hydrochloride | Antimalarial, binding to plasmpesin, a haemoglobin degrading enzyme unique to the malarial parasites |
|
| DCC2478 | Halofenate | Selective peroxisome proliferator-activated receptor gamma (PPAR-gamma) modulator with antilipidemic activity |
|
| DCC2479 | Haloprotac2 | Novel HaloPROTAC degrader, inducing degradation of HaloTag fusion proteins |
|
| DCC2480 | Haloquinone | Novel Wnt inhibitor, blocking Wnt signaling downstream of beta-Catenin |
|
| DCC2481 | Haploscleridamine | Novel inhibitor of cathepsin K (CatK) |
|
| DCC2482 | Haptamide B | Novel selective inhibitor of Hap2/3/4/5p mediated transcription in vivo. |
|
| DCC2483 | Harringtonolide | Natural antiproliferative, antifungal, antitumor agent, suppressing the epithelial-mesenchymal transition (EMT) process and inhibiting activation of the FAK/Src/STAT3 signaling pathway in A375 cells, targeting RACK1 to suppress cancer cell migration |
|
| DCC2484 | hat Inhibitor C107 | Novel p300/CBP HAT inhibitor |
|
| DCC2485 | Hatric | Precursor for HATRIC-based ligand receptor capture (HATRIC-LRC) |
|
| DCC2486 | Hbf-0079 | Hepatocellular carcinoma (HCC)-selective cytotoxin, suppressing AKT anti-apoptotic signaling |
|
| DCC2487 | Hc102a | Novel Inhibitor of Mycobacterium tuberculosis DosRST signaling and persistence |
|
| DCC2488 | Hc103a | Novel Inhibitor of Mycobacterium tuberculosis DosRST signaling and persistence |
|
| DCC2489 | Hc104a | Novel inhibitor of DosRST, inhibiting DosR DNA binding in a dose-dependent manner by directly targeting DosR |
|
| DCC2490 | Hc106a | Novel inhibitor of DosRST, inhibiting Mtb survival during hypoxia-induced NRP, directly targeting the sensor kinase heme, via a mechanism that is distinct from the oxidation and alkylation of heme previously observed with artemisinin (HC101A) |
|
| DCC2491 | Hca Xii-in-2c | Novel inhibitor of human carbonic anhydrase XII (hCA-XII), demonstrating significant antiproliferative activity against hypoxic tumor cell lines |
|
| DCC2492 | Hca-ix/xii-in-4m | Novel selective dual carbonic anhydrase IX and XII inhibitor |
|
| DCC2493 | Hci-2184 | Novel Nek2 inhibitor, successfully mitigating drug resistance in bortezomib-resistant multiple myeloma; Potent AXL kinase inhibitor |
|
| DCC2494 | Hcov-in-8n | Novel inhibitor of human coronavirus 229E (hCoV 229E) replication with an EC50 value of 5.5 µM |
|
| DCC2495 | HCT1026 | Selective modulator of amyloid-beta peptide degradation, regulating Abeta levels. |
|
| DCC2496 | Hct-13 | Novel copper-dependent cytotoxic agent, being highly potent against a panel of pancreatic, small cell lung carcinoma, prostate cancer, and leukemia models, with IC50 values in the low-to-mid nanomolar range |
|
